Navan (NASDAQ: NAVN) announced that Evotec (NASDAQ: EVO), a drug discovery and development company, has selected its platform to manage corporate travel and expense programs across its top global markets.

Evotec had previously managed travel and expense independently across different countries, relying on a mix of tools and manual processes. The company is now rolling out Navan across Germany, the UK, the U.S., Italy, and France.

The platform is intended to automate expense reconciliation from the point of transaction, replacing manual data entry and consolidating travel booking and expense management into a single system.

"Simplifying processes and strengthening operational excellence while enabling our employees with efficient tools are key priorities for Evotec," said Kay Prätorius, VP Procurement at Evotec. "Transitioning to the single, intuitive Navan platform will enhance the overall user experience, providing real-time visibility and control over our global travel and expense activities."

Evotec employs more than 4,500 people across sites in Europe and the U.S. The company works with all top 20 pharmaceutical companies and more than 800 biotechs.